Fig. 2.

EZH2 and miR-506–3p–induced increases in PARPi/cisplatin sensitivity in ovarian cancer cells.

(A,B) HeyA8 cells were transfected with 50 nM si-ctrl or si-EZH2. After 48 h, cells were reseeded for olaparib (A) or cisplatin (B) sensitivity assay. Cell viability was assessed by CCK8 assay. (C–E) HeyA8 cells were co-transfected with EZH2 without the 3′-UTR or empty vector (EV) together with 20 nM miR-506-3p or miR-ctrl. After 24 h, cells were harvested for western blot analysis (C) or reseeded for olaparib (D) or cisplatin (E) sensitivity assay.